Erlotinib Tablets IP 150mg
ERLOLIEVA 150 MG (Erlotinib Tablets IP 150mg) is a targeted anticancer medicine used in the treatment of certain types of lung cancer and pancreatic cancer. It contains Erlotinib Hydrochloride, a highly effective Epidermal Growth Factor Receptor (EGFR) inhibitor that helps slow down the growth and spread of cancer cells in the body. This medicine is commonly prescribed by oncologists as part of modern targeted cancer therapy protocols for patients with specific cancer types and genetic profiles.
Cancer develops when abnormal cells grow uncontrollably and spread to other parts of the body. In some cancers, proteins known as Epidermal Growth Factor Receptors (EGFR) play an important role in helping cancer cells survive, multiply, and spread. ERLOLIEVA 150 MG works by blocking these receptors, thereby interfering with cancer cell growth and reducing tumor progression.
Unlike traditional chemotherapy, Erlotinib is a targeted therapy that focuses on specific pathways involved in cancer development. This targeted approach helps improve treatment effectiveness in eligible patients while minimizing damage to healthy cells. As a result, Erlotinib has become an important treatment option in oncology care, especially for patients with EGFR-positive cancers.
ERLOLIEVA 150 MG is commonly prescribed for:
• Non-Small Cell Lung Cancer (NSCLC)
• EGFR Mutation-Positive Lung Cancer
• Advanced or Metastatic Lung Cancer
• Pancreatic Cancer (in combination with other treatments)
• Long-term targeted oncology treatment programs
This medicine may be used as a first-line treatment or after other cancer therapies depending on the patient's condition, treatment history, and medical requirements.
ERLOLIEVA 150 MG is manufactured under strict pharmaceutical quality standards to ensure safety, purity, and consistent therapeutic performance. It is intended strictly for use under the supervision of qualified healthcare professionals experienced in oncology treatment.
Patients receiving Erlotinib therapy may require regular medical monitoring, blood tests, liver function assessments, and imaging studies during treatment. Proper monitoring helps evaluate treatment response and manage potential side effects effectively.
Due to its effectiveness in targeted oncology therapy, ERLOLIEVA 150 MG has become an important medicine in modern cancer care and personalized treatment programs.
View Details
Nintedanib Softgelatin Capsules 150mg
NINDALIEVA 150 MG (Nintedanib Softgelatin Capsules 150 mg) is a prescription medicine used for the treatment of Idiopathic Pulmonary Fibrosis (IPF), Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs), and certain other chronic lung conditions as prescribed by healthcare professionals. It contains Nintedanib 150 mg, a tyrosine kinase inhibitor that helps slow the progression of lung fibrosis by targeting multiple pathways involved in tissue scarring and abnormal cell growth.
Idiopathic Pulmonary Fibrosis is a serious chronic lung disease characterized by progressive scarring of lung tissue. Over time, this scarring reduces the lungs' ability to transfer oxygen into the bloodstream, making breathing increasingly difficult. NINDALIEVA 150 MG helps slow the rate of lung function decline, supporting long-term respiratory health and improving disease management.
Nintedanib works by blocking specific growth factor receptors involved in the formation of fibrotic tissue. By inhibiting these pathways, the medicine helps reduce excessive scar tissue development in the lungs and may delay disease progression in eligible patients.
In addition to pulmonary fibrosis, Nintedanib is also used in selected patients with other progressive interstitial lung diseases and may be prescribed as part of comprehensive respiratory care programs.
NINDALIEVA 150 MG is commonly prescribed for:
• Idiopathic Pulmonary Fibrosis (IPF)
• Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
• Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
• Chronic Progressive Lung Fibrosis
• Long-Term Pulmonary Disease Management
• Specialist Respiratory Care Programs
The medicine is manufactured under strict pharmaceutical quality standards to ensure safety, effectiveness, and consistent therapeutic performance. It should only be used under the supervision of qualified healthcare professionals experienced in respiratory medicine.
Patients receiving Nintedanib therapy may require regular monitoring of liver function, lung function, overall treatment response, and routine medical assessments. These evaluations help healthcare providers optimize treatment outcomes and identify potential side effects early.
Due to its effectiveness in slowing disease progression and supporting long-term respiratory care, NINDALIEVA 150 MG has become an important treatment option in modern pulmonary medicine.
View Details
Crizotinib Tablets 250mg
CRIZLIEVA 250 mg contains Crizotinib, an oral tyrosine kinase inhibitor (TKI). It targets ALK (anaplastic lymphoma kinase), ROS1, and MET receptors, inhibiting signaling pathways that drive tumor cell growth and survival. It is especially effective in ALK-positive and ROS1-positive lung cancers.
View Details
Afatinib Tablets IP 30mg
AFALIEVA 30 mg contains Afatinib, an oral irreversible ErbB family tyrosine kinase inhibitor (TKI). It covalently inhibits EGFR (ErbB1) and HER2 (ErbB2) receptors, blocking downstream signaling pathways involved in tumor cell growth and survival. It is effective in EGFR mutation–positive lung cancers.
View Details
Afatinib Tablets IP 40mg
AFALIEVA 40 mg contains Afatinib, an oral irreversible ErbB family tyrosine kinase inhibitor (TKI). It blocks EGFR (ErbB1) and HER2 (ErbB2) signaling by covalently binding to the receptor, thereby inhibiting tumor cell growth and survival. Afatinib is effective against tumors with EGFR activating mutations.
View Details
Lenvatinib Capsules 10mg
LENVALIEVA 10 mg contains Lenvatinib, an oral multi-targeted tyrosine kinase inhibitor (TKI). It blocks receptors involved in tumor angiogenesis and growth, including VEGFR 1–3, FGFR 1–4, PDGFR-α, RET, and KIT, leading to inhibition of tumor blood vessel formation and cancer cell proliferation.
View Details
Pemetrexed Injection IP 500mg
ALIMLIEVA 500 mg contains Pemetrexed, a chemotherapy (anticancer) drug classified as a multitargeted antifolate antimetabolite. It inhibits key enzymes involved in purine and pyrimidine synthesis, leading to inhibition of DNA and RNA synthesis and cancer cell death. It is mainly used in non-squamous lung cancers.
View Details
Pemetrexed Injection IP 100mg
ALIMLIEVA 100 mg contains Pemetrexed, a chemotherapy (anticancer) medicine classified as a multitargeted antifolate. It inhibits several enzymes involved in DNA and RNA synthesis, leading to suppression of cancer cell growth. It is mainly used in non-squamous lung cancers.
View Details
